Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2020

View Archived Issues

Picturing molecular alterations

AC Immune to advance anti-TDP-43 antibody toward clinical development

IL12-L19L19 trial underway in advanced solid carcinomas and DLBCL

Phase II trial of EPX-100 underway in children with Dravet syndrome

Novel humanized platelet mouse model predicts efficacy of experimental antiplatelet drugs

Chinese investigators patent IDO1 inhibitors

Minghui Pharmaceutical presents new BTK inhibitors

Biogen synthesizes new IRAK-4 inhibitors

Dogma Therapeutics describes PCSK9 inhibitors

BiSiChem identifies new ALK inhibitors

Regenxbio reports positive interim phase I/IIa data and program updates for RGX-314

In vitro data show VERU-111 suppresses key cytokines responsible for severe ARDS in COVID-19

Independent IRB grants approval for phase II study of LSALT peptide in severe COVID-19

Catabasis and Gates MRI to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis

Gallium-68-labeled denosumab synthesized for PET imaging of tumor microenvironment

Probiotics affect brain peptidome via gut-brain axis

SEMA3C identified as promising therapeutic target in bladder cancer

AC Immune describes enhanced alpha-synuclein PET tracers

First-in-human study of [124I]JS-001 PET/CT and PET/MR in patients with melanoma

European Commission grants conditional marketing authorization for Hepcludex

Phase I/II trial set to evaluate ARO-ENaC in cystic fibrosis

FDA clears IND application to initiate clinical trial of niclosamide in patients with COVID-19

Topline data from phase II/III registration study of pegloprastide

Positive phase I data for COVID-19 vaccine candidate NVX-CoV2373

Aerpio announces funding from MTEC to evaluate razuprotafib in patients with COVID-19

Nabota demonstrates palliative effect on bruxism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...